Stockscreener 앱 받기
4.2381
1.63%
0.0681
시간 외 거래:
4.24
0.0019
+0.04%
전일 마감가:
$4.17
열려 있는:
$4.255
하루 거래량:
9,148
Relative Volume:
1.76
시가총액:
$211.92M
수익:
-
순이익/손실:
-
주가수익비율:
-5.7732
EPS:
-0.7341
순현금흐름:
-
1주 성능:
+8.39%
1개월 성능:
-2.19%
6개월 성능:
+15.01%
1년 성능:
-28.29%
1일 변동 폭
$3.9475
$4.28
1주일 범위
$3.93
$4.49
52주 변동 폭
$2.55
$6.4229
Genfit Adr Stock (GNFT) Company Profile
GNFT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GNFT
Genfit Adr
|
4.2381 | 208.51M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.90 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
470.27 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.42 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
815.61 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
316.15 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Genfit Adr Stock (GNFT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-19 | 재개 | H.C. Wainwright | Buy |
| 2021-12-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-07-23 | 업그레이드 | Stifel | Hold → Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Underperform |
| 2020-05-13 | 다운그레이드 | Kepler | Buy → Reduce |
| 2020-05-12 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-05-12 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2019-10-29 | 재확인 | B. Riley FBR | Buy |
| 2019-06-25 | 개시 | Stifel | Hold |
| 2019-04-24 | 개시 | SVB Leerink | Outperform |
| 2019-04-22 | 개시 | Barclays | Overweight |
모두보기
Genfit Adr 주식(GNFT)의 최신 뉴스
European ADRs Start The Week With Small Gains Stateside - Finimize
FY2025 Earnings Estimate for GENFIT Issued By HC Wainwright - Defense World
FY2025 EPS Estimates for GENFIT Lifted by Leerink Partnrs - Defense World
HC Wainwright Has Pessimistic View of GENFIT FY2025 Earnings - MarketBeat
GENFIT (NASDAQ:GNFT) Price Target Lowered to $7.00 at HC Wainwright - Defense World
HC Wainwright Has Lowered Expectations for GENFIT (NASDAQ:GNFT) Stock Price - MarketBeat
European ADRs Dip Slightly As Biotech Stocks Jump And Drop - Finimize
GENFIT (NASDAQ:GNFT) Coverage Initiated by Analysts at HC Wainwright - Defense World
European Biopharma ADRs: A Strategic Play in a Volatile Market - AInvest
European ADRs Tick Up As Pharma And Telecom Lead Gains - Finimize
GENFIT (NASDAQ:GNFT) Shares Up 0.7% – Time to Buy? - Defense World
European ADRs: Navigating Sectoral Divergence in a Volatile Market - AInvest
European Biopharma Leads Gains In ADR Market Surge - Finimize
European Biotech ADRs Lead the Charge: A Sector on the Verge of Breakthrough Growth - AInvest
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
European ADRs Show Optimism As Genfit Leads Gains - Finimize
European ADRs See Mixed Results With Modest Gains - Finimize
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading - TradingView
European ADRs Climb As Biopharmaceuticals Lead The Charge - Finimize
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Higher in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for Week - TradingView
European Equities Traded in the US as American Depositary Receipts Surge Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis - GlobeNewswire
Ipsen confirms U.S. FDA grants priority review for New Drug - GlobeNewswire
Results from Ipsen’s ELATIVE® pivotal Phase III trial of - GlobeNewswire
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire
Genfit Adr (GNFT) 재무 분석
Genfit Adr (GNFT)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
4.09%
0.09%
자본화:
|
볼륨(24시간):